mycosis fungoides (Cancer)
Information
- Disease name
- mycosis fungoides
- Disease ID
- DOID:8691
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04541017 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | April 6, 2021 | June 30, 2025 |
| NCT03695471 | Active, not recruiting | Phase 2 | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | December 20, 2018 | October 11, 2024 |
| NCT01352520 | Active, not recruiting | Phase 2 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | June 2011 | January 31, 2026 |
| NCT02953301 | Active, not recruiting | Phase 2 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | November 2016 | June 2024 |
| NCT00091559 | Completed | Phase 2 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | February 3, 2005 | March 13, 2006 |
| NCT00038376 | Completed | Phase 2 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | May 8, 1990 | June 30, 2005 |
| NCT05303480 | Completed | N/A | Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides | December 7, 2021 | December 8, 2022 |
| NCT00168064 | Completed | Phase 2 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | May 2006 | August 2011 |
| NCT00177190 | Completed | In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) | June 2002 | January 2006 | |
| NCT00047060 | Completed | Phase 1/Phase 2 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | July 30, 2002 | January 24, 2019 |
| NCT00178841 | Completed | Phase 2 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | June 2005 | March 2007 |
| NCT00185965 | Completed | Phase 1/Phase 2 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | July 2004 | March 2010 |
| NCT00221039 | Completed | Phase 4 | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | April 2, 2004 | April 5, 2011 |
| NCT00254332 | Completed | Effect of Denileukin Diftitox on Immune System in CTCL Patients | November 2005 | September 2007 | |
| NCT00368784 | Completed | T Cell Repertoire Analysis of Immune Mediated Skin Diseases | January 2007 | November 2020 | |
| NCT04955340 | Completed | Phase 1 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | October 12, 2021 | January 19, 2022 |
| NCT00535470 | Completed | Phase 2 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | July 2007 | March 2011 |
| NCT00611208 | Completed | Phase 2 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | January 2008 | November 2016 |
| NCT01134341 | Completed | Phase 1 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | March 2010 | August 2015 |
| NCT01396070 | Completed | Phase 2 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | May 2011 | May 2016 |
| NCT04185220 | Completed | Phase 1 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | February 26, 2020 | May 18, 2022 |
| NCT03905135 | Completed | Phase 1 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | June 7, 2019 | May 17, 2022 |
| NCT01578499 | Completed | Phase 3 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) | June 11, 2012 | July 6, 2018 |
| NCT01590732 | Completed | Phase 1 | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | October 29, 2012 | May 2, 2018 |
| NCT02883517 | Completed | Cell-free Circulating DNA in Primary Cutaneous Lymphomas | November 22, 2016 | December 16, 2019 | |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT00050999 | Completed | Phase 4 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | June 1995 | December 2006 |
| NCT00051012 | Completed | Phase 4 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | September 1995 | December 2006 |
| NCT03380026 | Completed | Phase 2 | Mechlorethamine Induced Contact Dermatitis Avoidance Study | December 13, 2017 | December 13, 2020 |
| NCT02822586 | Completed | Phase 1 | TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | December 19, 2016 | April 29, 2019 |
| NCT02296164 | Completed | Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma | November 12, 2014 | October 17, 2018 | |
| NCT05205902 | Not yet recruiting | Phase 3 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides | February 2022 | February 2031 |
| NCT05538988 | Not yet recruiting | Phase 1/Phase 2 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma | December 2024 | March 2026 |
| NCT06421571 | Recruiting | The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients | February 21, 2023 | December 2025 | |
| NCT00177268 | Recruiting | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research | October 2004 | January 2032 | |
| NCT03587844 | Recruiting | Phase 2 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | July 3, 2018 | July 2025 |
| NCT03602157 | Recruiting | Phase 1 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | December 12, 2018 | September 30, 2041 |
| NCT04118868 | Recruiting | Phase 1 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | August 31, 2022 | March 27, 2024 |
| NCT04234048 | Recruiting | Phase 1 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | December 18, 2023 | November 2025 |
| NCT04256018 | Recruiting | Phase 2 | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | March 30, 2020 | August 2024 |
| NCT04676087 | Recruiting | Phase 1/Phase 2 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | April 21, 2021 | April 28, 2025 |
| NCT04904146 | Recruiting | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | April 2, 2021 | April 2027 | |
| NCT04960618 | Recruiting | Phase 2 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | October 1, 2021 | July 2025 |
| NCT05357794 | Recruiting | Phase 2 | Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | October 13, 2022 | June 30, 2024 |
| NCT05414500 | Recruiting | Phase 1 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | May 1, 2023 | June 30, 2025 |
| NCT05526638 | Recruiting | N/A | Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides | January 1, 2023 | May 30, 2023 |
| NCT05680558 | Recruiting | Phase 2 | Photopheresis in Early-stage Mycosis Fungoides | May 8, 2021 | July 25, 2026 |
| NCT05838599 | Recruiting | Early Phase 1 | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides | July 24, 2023 | February 1, 2026 |
| NCT05855460 | Recruiting | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | January 12, 2023 | June 2023 | |
| NCT05872854 | Recruiting | Phase 2 | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light | August 21, 2023 | May 31, 2025 |
| NCT05879458 | Recruiting | Phase 2 | Ritlecitinib in CTCL | May 17, 2023 | April 2026 |
| NCT05904522 | Recruiting | N/A | Histopathological Changes in Mycosis Fungoides | May 1, 2023 | October 31, 2024 |
| NCT05944562 | Recruiting | Phase 1 | Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome | January 9, 2024 | January 31, 2030 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT06207812 | Recruiting | Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis | January 19, 2024 | January 12, 2026 | |
| NCT06235281 | Recruiting | Early Phase 1 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) | January 18, 2024 | September 1, 2029 |
| NCT02848274 | Recruiting | ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | October 2016 | March 2027 | |
| NCT03398161 | Recruiting | Phase 2 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | January 6, 2018 | December 31, 2024 |
| NCT05138458 | Suspended | Phase 1/Phase 2 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | December 15, 2021 | October 2025 |
| NCT02811783 | Terminated | Phase 3 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL | January 2017 | September 2022 |
| NCT01445340 | Terminated | Phase 1 | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | April 21, 2007 | June 29, 2012 |
| NCT00496743 | Terminated | N/A | Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides | January 2002 | January 2006 |
| NCT01609816 | Terminated | Phase 1 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | February 12, 2015 | October 9, 2018 |
| NCT03789864 | Terminated | N/A | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides | October 7, 2019 | May 1, 2024 |
| NCT01556828 | Terminated | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | June 2011 | June 2014 | |
| NCT00129415 | Terminated | Phase 1/Phase 2 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | August 2000 | January 2011 |
| NCT02341209 | Terminated | Phase 2 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma | February 6, 2018 | February 6, 2021 |
| NCT02890368 | Terminated | Phase 1 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | September 2016 | March 31, 2020 |
| NCT02323659 | Terminated | Phase 4 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas | June 1, 2014 | March 31, 2018 |
| NCT00985140 | Terminated | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | June 2009 | May 2012 | |
| NCT00127881 | Terminated | Phase 3 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | July 2005 | |
| NCT02881749 | Unknown status | Phase 2 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | September 2016 | |
| NCT03267407 | Unknown status | Vietnam Cryptococcal Retention in Care Study - Version 2.1 | August 14, 2015 | March 31, 2018 | |
| NCT02542124 | Unknown status | Phase 2 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | December 2015 | May 2019 |
| NCT02943642 | Unknown status | Phase 2 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | January 2017 | May 2020 |
| NCT00157274 | Unknown status | Phase 2 | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | July 2005 | July 2008 |
| NCT00226993 | Withdrawn | Phase 1/Phase 2 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | March 2005 | |
| NCT03288818 | Withdrawn | Phase 2 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides | August 2018 | December 2021 |
| NCT02301494 | Withdrawn | N/A | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma | April 2020 | April 2023 |
- Disase is a (Disease Ontology)
- DOID:0060061
- Cross Reference ID (Disease Ontology)
- GARD:3863
- Cross Reference ID (Disease Ontology)
- ICD10CM:C84.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:202.1
- Cross Reference ID (Disease Ontology)
- ICDO:9700/3
- Cross Reference ID (Disease Ontology)
- MESH:D009182
- Cross Reference ID (Disease Ontology)
- MIM:254400
- Cross Reference ID (Disease Ontology)
- NCI:C3246
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:118618005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0026948
- Exact Synonym (Disease Ontology)
- mycosis fungoides lymphoma
- ICD10 preferred id (Insert disease from ICD10)
- D0002255
- ICD10 class code (Insert disease from ICD10)
- C84.0
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009182